FDA use of Cholestin marketing, manufacture to resolve status "reasonable" -- agency.
This article was originally published in The Tan Sheet
Executive Summary
FDA RELIANCE ON CHOLESTIN MARKETING, MANUFACTURING TO DETERMINE STATUS of the product as an unapproved new drug "is a reasonable application" of the Dietary Supplement Health & Education Act, the agency maintains in a June 9 memorandum filed in Salt Lake City federal court. The memorandum responds to Pharmanex' motion for a preliminary injunction that would lift an FDA ban on imports of red yeast rice for the production of Cholestin.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning